SCHEDULE: Krystal Biotech Insiders Report 11.5% Stake

Krish S. Krishnan and Suma M. Krishnan jointly report beneficial ownership of 3,388,283 shares, representing 11.5% of Krystal Biotech, Inc. common stock.

Summary

• Krish S. Krishnan and Suma M. Krishnan have jointly filed an amendment to their Schedule 13G, reporting their combined beneficial ownership of Krystal Biotech, Inc. common stock.
• The total number of shares beneficially owned by both individuals is 3,388,283, which constitutes 11.5% of the company's outstanding common stock.
• This ownership percentage is based on 29,479,756 shares of common stock outstanding as of April 29, 2026, as reported by Krystal Biotech in its Form 10-Q filed on May 4, 2026.
• The filing details the breakdown of share ownership, including direct holdings, shares held in trusts (SMK Trust FBO KSK, Krishnan Spousal Trust, Krishnan Family Trust), and shares issuable upon exercise of stock options held by Mr. Krishnan and Mrs. Krishnan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine ownership disclosure by key insiders and does not provide new operational or financial information.

Positives

• Significant combined ownership stake of 11.5% by key insiders (Chairman & CEO and President R&D) indicates strong alignment with the company's performance.
• The filing clarifies the beneficial ownership structure, including holdings in various trusts and stock options, providing transparency to investors.

Negatives

• The filing does not contain any negative financial or operational information; it is purely an ownership disclosure.

Risks

• Potential for future stock sales by these insiders could impact share price, although no such intention is stated.
• Concentration of ownership among a few individuals could lead to governance concerns if not managed appropriately.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Management Comments

• Krish S. Krishnan certifies that the information set forth in this statement is true, complete and correct, and signs as Chairman & CEO.
• Suma M. Krishnan certifies that the information set forth in this statement is true, complete and correct, and signs as Director, President R&D.

Industry Context

StockSavvy.ai notes that significant insider ownership, as reported by Krystal Biotech's key executives, often signals strong conviction in the company's prospects, though it is primarily an ownership disclosure rather than an operational update.

Comparison to Industry Standards

• In the biotechnology sector, insider ownership percentages can vary widely. A 11.5% stake held jointly by the CEO and President of R&D is a substantial holding, often seen in founder-led or closely held companies, indicating a high degree of personal investment in the company's success.

Stakeholder Impact

• Shareholders: The substantial insider ownership may provide some comfort regarding management's commitment, but the filing itself does not directly impact share value or company operations.

Next Steps

• Continued monitoring of insider trading activity and future Schedule 13G filings for any changes in ownership.

Key Dates

Keywords

Krystal Biotech, Schedule 13G, Beneficial Ownership, Krish S. Krishnan, Suma M. Krishnan, Insider Holdings, Common Stock, SEC Filing, Ownership Disclosure